ATENOLOL tablet

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Active ingredient:

Atenolol (UNII: 50VV3VW0TI) (Atenolol - UNII:50VV3VW0TI)

Available from:

Mutual Pharmaceutical Company, Inc.

INN (International Name):

Atenolol

Composition:

Atenolol 25 mg

Administration route:

ORAL

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of

Product summary:

Atenolol tablets, USP are supplied as follows: Atenolol tablets 25 mg white, round, unscored, debossed MP 9 Atenolol tablets 50 mg white, round, scored, debossed MP 146 Atenolol tablets 100 mg white, round, unscored, debossed MP 147 Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature] DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.

Authorization status:

Abbreviated New Drug Application

Summary of Product characteristics

ATENOLOL- ATENOLOL TABLET
MUTUAL PHARMACEUTICAL COMPANY, INC.
----------
ATENOLOL TABLETS USP
RX ONLY
DESCRIPTION
Atenolol, a synthetic, beta -selective (cardioselective)
adrenoreceptor blocking agent, may be
chemically described as benzeneacetamide,
4-[2'-hydroxy-3'-[(1-methylethyl) amino] propoxy]-.
The molecular and structural formulas are:
C
H N O
Atenolol (free base) has a molecular weight of 266. It is a relatively
polar hydrophilic compound with a
water solubility of 26.5 mg/mL at 37°C and a log partition
coefficient (octanol/water) of 0.23. It is
freely soluble in 1N HCl (300 mg/mL at 25°C) and less soluble in
chloroform (3 mg/mL at 25°C).
Atenolol is available as 25 mg, 50 mg, and 100 mg tablets for oral
administration.
Inactive ingredients are: magnesium stearate, microcrystalline
cellulose, povidone, and sodium starch
glycolate.
CLINICAL PHARMACOLOGY
Atenolol is a beta -selective (cardioselective) beta-adrenergic
receptor blocking agent without
membrane stabilizing or intrinsic sympathomimetic (partial agonist)
activities. This preferential effect is
not absolute, however, and at higher doses, atenolol inhibits beta
-adrenoreceptors, chiefly located in
the bronchial and vascular musculature.
PHARMACOKINETICS AND METABOLISM
In man, absorption of an oral dose is rapid and consistent but
incomplete. Approximately 50% of an oral
dose is absorbed from the gastrointestinal tract, the remainder being
excreted unchanged in the feces.
Peak blood levels are reached between two (2) and four (4) hours after
ingestion. Unlike propranolol or
metoprolol, but like nadolol, atenolol undergoes little or no
metabolism by the liver, and the absorbed
portion is eliminated primarily by renal excretion. Over 85% of an
intravenous dose is excreted in urine
within 24 hours compared with approximately 50% for an oral dose.
Atenolol also differs from
propranolol in that only a small amount (6%–16%) is bound to
proteins in the plasma. This kinetic
profile results in relatively consistent plasma drug levels with about
a fourf